JB
CADL icon

Julian Baker’s Candel Therapeutics CADL Stock Holding History

Julian Baker’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-355,112
Closed -$1.8M – 92
2025
Q2 		$1.8M Sell
355,112
-2,082,077
-85% -$10.7M 0.02% 77
2025
Q1 		$13.8M Sell
2,437,189
-544,794
-18% -$4.45M 0.15% 40
2024
Q4 		$25.9M Buy
+2,981,983
New +$17.6M 0.28% 39

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Julian Baker's CADL Position: Q3 2025 in Review

Julian Baker sold out of Candel Therapeutics (CADL) in Q3 2025, closing a stake of 355,112 shares — an estimated $1.8M sold.

Julian Baker first reported a position in CADL in Q4 2024 and held it in 3 quarters. The position peaked at $25.9M in Q4 2024. 81 funds tracked by Wall St. Rank hold CADL as of Q3 2025.

  • Julian Baker reported no remaining Candel Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Julian Baker sold 355,112 Candel Therapeutics shares in Q3 2025, an estimated $1.8M.
  • Julian Baker first reported a position in Candel Therapeutics in Q4 2024 and held it in 3 quarters.
  • Julian Baker's Candel Therapeutics position peaked at $25.9M in Q4 2024.
  • 81 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2025.

Based on Baker Bros. Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.